Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Biotech Company Secures $453 Million Award For Covid-19 Oral Pill Candidate

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate.
Vaxart, Inc. (Nasdaq: VXRT), a biotechnology company known for its innovative oral vaccines, has announced a significant milestone in the development of its COVID-19 oral pill vaccine candidate. The company received a project award valued at up to $453 million through the Rapid Response Partnership Vehicle (RRPV), a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA). PART OF THE Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), this funding aims to support a Phase 2b comparative study evaluating Vaxart’s oral vaccine against an FDA-approved mRNA vaccine comparator. $Vaxart(VXRT.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
+0
Translate
Report
3040 Views
Comment
Sign in to post a comment
    178Followers
    0Following
    400Visitors
    Follow